Comparison of JAK inhibitors and biologics with respect to pain reduction in patients with rheumatoid arthritis: data from the KOBIO registry.
文献摘要
Background/aims To compare the pain-reducing efficacy of Janus kinase inhibitors (JAKis) and biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA). Methods Patients with RA enrolled in the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry were grouped according to use of JAKis, TNFis, and non-TNFi bDMARDs. The primary outcome was to compare the changes in pain on a numeric rating scale (NRS, range 0-10) between enrolment and first follow-up. Logistic regression analysis was performed to identify the factors associated with a low pain NRS score ( Results The analysis included 2,415 patients with RA in the JAKis (n = 422), TNFis (n = 1,148), and non-TNFi bDMARDs groups (n = 845). The change in pain NRS was significantly greater in the JAKis group than in the TNFis group (2.8 ± 2.5 vs. 2.3 ± 2.9, respectively; p Conclusions Among patients who achieved treatment response and remained on therapy, JAKis were associated with greater improvement in pain control than TNFis.